Stanford Cancer Institute
Cancer Cell Therapy

Non-Hodgkins Lymphoma

≥ 18 Yrs

Diffused Large B-Cell Lymphoma

Relapsed or refractory disease after CD19-directed therapy

CCT5029
Phase I/Ⅱ
Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies
Pl: Muffy Stanford

CCT5006-EXP
Expanded Access Axicabtagene Ciloleucel in Tx Relapsed/Refractory T-plant-Ineligible Aggressive NHL
Pl: Miklos Kite Pharma

CCT5016
Managed Access Program (MAP) CTL019 in ALL or DLBCL
Pl: Miklos Stanford

CCT5001
Phase I CD19/CD22 Chimeric Antigen Receptor(CAR) T Cells in Recurrent/Refractory B Cell Malignancies
Pl: Miklos Stanford

CCT5024
Phase I/Ⅱ ALLO-501 (AntiCD19 Allogeneic CAR TCell Tx) Relapsed/Refractory Large B-Cell & Follicular Lymphoma
Pl: Miklos Allogene

CCT5020
Phase Ib Tisagenlecleucel in Combo w/ Bortezomib in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Pl: Parveen Sponsor: Novartis

CCT5018
Phase I/Ⅱ Axicabtagene Ciloleucel in Combo w/ Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Pl: Parveen Sponsor: Kite Pharma

CCT5037
Phase I/Ⅱ Axicabtagene Ciloleucel +/- Lenalidomide in Relapsed/Refractory Large B-cell Lymphoma
Pl: Parveen Sponsor: Pending

CCT5036
Phase I/Ⅱ ALLO-501A Anti-CD19 Allogeneic CAR T-Cell Tx in Relapsed/Refractory Large B-Cell Lymphoma
Pl: Miklos Sponsor: Pending

CCT5043
Phase I/Ⅱ PBCAR20A in Relapsed/Refractory (R/R) NHL or R/R CLL or Small Lymphocytic Lymphoma
Pl: Miklos Sponsor: Pending

CCT5038
Phase II/Ⅲ Lisocabtagene Maraleucel (JCAR017) in 2nd-Line Therapy in Adult Aggressive B-cell NHL
Pl: Gupta Sponsor: Juno Therapeutics

Relapsed or refractory disease second-line

Transplant Ineligible

KEY
- Pending
- Open for Enrollment
- Link
- Optional Path
- Trial Posting
- Extension Study
- Immunotherapy
- Enrollment on Hold

Please mark up a copy using black ink and email changes to SRC-office@stanford.edu